Literature DB >> 21866231

Sildenafil Increases Systemic Saturation and Reduces Pulmonary Artery Pressure in Patients with Failing Fontan Physiology.

Gira S Morchi1, D Dunbar Ivy, Mark C Duster, Lori Claussen, Kak-Chen Chan, Joseph Kay.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the effect of sildenafil in patients with failing Fontan physiology.
DESIGN: A retrospective chart review was performed to compare history and available data in patients with Fontan circulations before and after starting sildenafil. The paired and unpaired Student's t-tests were used for statistical analyses. PATIENTS: Six patients at our institution with Fontan physiology, persistent symptoms of cyanosis or effusion, and poor hemodynamics as measured in the catheterization laboratory were placed on sildenafil. One patient was not included in the analysis because of insufficient length of treatment. All patients had symptoms of failing Fontan hemodynamics with either persistent cyanosis or effusions. In this group, the mean pulmonary artery pressure was greater than 15 mm Hg (17.4 ± 1.5 mm Hg) with mean estimated pulmonary vascular resistance of 3.5 ± 1.0 Wood units × m(2) prior to starting sildenafil.
RESULTS: Sildenafil significantly increased the systemic arterial oxyhemoglobin saturation in this group (82.8 ± 7.3% pre-treatment vs. 91.0 ± 5.5% post-treatment, P = .017). In the four out of five patients who have had follow-up catheterizations, there was a significant decrease in pulmonary artery pressure (17.4 ± 1.5 mm Hg pre-treatment vs. 13.8 ± 2.1 mm Hg post-treatment, P = .018) and in estimated pulmonary vascular resistance pre- and post-sildenafil treatment (3.5 ± 1.0 Wood units × m(2) pre-treatment vs. 2.0 ± 0.4 Wood units × m(2) post-treatment, P = .031).
CONCLUSIONS: Sildenafil may be a useful adjunct to therapy in patients with failing Fontan physiology likely through its function as a pulmonary vasodilator.

Entities:  

Year:  2009        PMID: 21866231      PMCID: PMC3159127          DOI: 10.1111/j.1747-0803.2008.00237.x

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  11 in total

Review 1.  The Fontan circulation.

Authors:  Marc Gewillig
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

2.  Nitric oxide precursors and congenital cardiac surgery: a randomized controlled trial of oral citrulline. Definition of pulmonary hypertension in Fontan circulation?

Authors:  Maurice Beghetti; Yacine Aggoun; Eduardo Da Cruz
Journal:  J Thorac Cardiovasc Surg       Date:  2006-12       Impact factor: 5.209

3.  Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome.

Authors:  Keiji Haseyama; Gengi Satomi; Satoshi Yasukochi; Hikoro Matsui; Yorikazu Harada; Shunji Uchita
Journal:  J Thorac Cardiovasc Surg       Date:  2006-11       Impact factor: 5.209

4.  Outcome after a "perfect" Fontan operation.

Authors:  F Fontan; J W Kirklin; G Fernandez; F Costa; D C Naftel; F Tritto; E H Blackstone
Journal:  Circulation       Date:  1990-05       Impact factor: 29.690

5.  Early and intermediate results of the Fontan procedure at moderately high altitude.

Authors:  R W Day; G S Orsmond; J E Sturtevant; J A Hawkins; D B Doty; E C McGough
Journal:  Ann Thorac Surg       Date:  1994-01       Impact factor: 4.330

6.  Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan.

Authors:  Orhan Uzun; Joon Kwang Wong; Vinaj Bhole; Oliver Stumper
Journal:  Ann Thorac Surg       Date:  2006-12       Impact factor: 4.330

7.  Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure.

Authors:  Max B Mitchell; David N Campbell; Dunbar Ivy; Mark M Boucek; Henry M Sondheimer; Biagio Pietra; Bibhuti B Das; Joseph R Coll
Journal:  J Thorac Cardiovasc Surg       Date:  2004-11       Impact factor: 5.209

8.  Inhaled nitric oxide therapy after Fontan-type operations.

Authors:  Naoki Yoshimura; Masahiro Yamaguchi; Shigeteru Oka; Masahiro Yoshida; Hirohisa Murakami; Tetsuro Kagawa; Takeshi Suzuki
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

9.  Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.

Authors:  Ingram Schulze-Neick; Paulina Hartenstein; Jia Li; Brigitte Stiller; Nicole Nagdyman; Michael Hübler; Ghazwan Butrous; Andy Petros; Peter Lange; Andrew N Redington
Journal:  Circulation       Date:  2003-09-09       Impact factor: 29.690

10.  Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation.

Authors:  Sotiria C Apostolopoulou; John Papagiannis; Spyridon Rammos
Journal:  J Heart Lung Transplant       Date:  2005-08       Impact factor: 10.247

View more
  10 in total

1.  Predictors of sildenafil effects on exercise capacity in adolescents and adults with Fontan circulation.

Authors:  Alfred Hager; Ruth Weber; Jan Müller; John Hess
Journal:  Clin Res Cardiol       Date:  2014-03-18       Impact factor: 5.460

2.  Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  David J Goldberg; Benjamin French; Michael G McBride; Bradley S Marino; Nicole Mirarchi; Brian D Hanna; Gil Wernovsky; Stephen M Paridon; Jack Rychik
Journal:  Circulation       Date:  2011-03-07       Impact factor: 29.690

Review 3.  Pulmonary Hypertension in Children.

Authors:  Dunbar Ivy
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

4.  Effect of Sildenafil on Pressure-Volume Loop Measures of Ventricular Function in Fontan Patients.

Authors:  Ryan J Butts; Shahryar M Chowdhury; George H Baker; Varsha Bandisode; Andrew J Savage; Andrew M Atz
Journal:  Pediatr Cardiol       Date:  2015-09-26       Impact factor: 1.655

Review 5.  Current challenges in pediatric pulmonary hypertension.

Authors:  Shinichi Takatsuki; David Dunbar Ivy
Journal:  Semin Respir Crit Care Med       Date:  2013-09-13       Impact factor: 3.119

Review 6.  Sildenafil in pediatric pulmonary arterial hypertension.

Authors:  A K Dhariwal; S B Bavdekar
Journal:  J Postgrad Med       Date:  2015 Jul-Sep       Impact factor: 1.476

Review 7.  Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children.

Authors:  Benjamin S Frank; D Dunbar Ivy
Journal:  Children (Basel)       Date:  2018-03-23

8.  Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

Authors:  Devashis Mukherjee; Girija G Konduri
Journal:  Compr Physiol       Date:  2021-06-30       Impact factor: 8.915

Review 9.  State of the art of the Fontan strategy for treatment of univentricular heart disease.

Authors:  Jelle P G van der Ven; Eva van den Bosch; Ad J C C Bogers; Willem A Helbing
Journal:  F1000Res       Date:  2018-06-27

10.  Pulmonary Vasodilator Therapy in Children with Single Ventricle Physiology: Effects on Saturation and Pulmonary Arterial Pressure.

Authors:  Ida Jeremiasen; Karin Tran-Lundmark; Nikmah Idris; Phan-Kiet Tran; Shahin Moledina
Journal:  Pediatr Cardiol       Date:  2020-07-30       Impact factor: 1.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.